Premium
Modification of plant N‐glycans processing: The future of producing therapeutic protein by transgenic plants
Author(s) -
Chen Min,
Liu Xianwei,
Wang Zhankun,
Song Jing,
Qi Qingsheng,
Wang Peng George
Publication year - 2005
Publication title -
medicinal research reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.868
H-Index - 130
eISSN - 1098-1128
pISSN - 0198-6325
DOI - 10.1002/med.20022
Subject(s) - golgi apparatus , glycoprotein , endoplasmic reticulum , glycan , glycosyltransferase , transgene , genetically modified crops , biochemistry , glycosylation , biology , recombinant dna , enzyme , microbiology and biotechnology , gene
Transgenic plants are regarded as one of the most promising systems for the production of human therapeutic proteins. The number of therapeutic proteins successfully produced in plants is steadily arising. However, the glycoproteins normally produced from plants are not the same as native therapeutic proteins produced from mammals or humans. In addition to in vitro enzymatic modeling glycoproteins, there are two gene manipulation strategies to humanize plant N ‐glycans connected to the glycoproteins. One is retaining the recombinant glycoproteins in endoplasmic reticulum (ER), the site where few specific modifications of N ‐glycans occurs. The other is inhibiting the plant endogenous Golgi glycosyltransferase and/or adding new glycosyltransferase from mammalians. In this review, the biosynthesis of N ‐glycans in plants, the modification of the plant N ‐glycans processing will be discussed. © 2004 Wiley Periodicals, Inc.